FIGURE 1.
FIGURE 2.
FIGURE 3.
FIGURE 4.
Treatment outcome in 58 patients with post-treatment evaluation, post-treatment evaluation being done three to six months after the end of treatment
| Treatment outcome | Number of patients |
|---|---|
| Complete remission | 46 (79.3%) |
| Partial remission | 10 (17.2%) |
| Stable disease | 1 (1.7%) |
| Progressive disease | 1 (1.7%)* |
Patients’ characteristics
| Males | Females | All | |
|---|---|---|---|
| Number of patients | 30 (40.5%) | 44 (59.5%) | 74 |
| Median age, years | 72 (range 41 – 89) | 67.5 (range 34 – 89) | 68 |
| Lymphoma type | |||
| - Marginal zone lymphoma (MALT) | 21/30 (70.0%) | 32/44 (72.7%) | 53/74 (71.6%) |
| - Mantle cell lymphoma (MCL) | 6/30 (20.0%) | 3/44 (6.8%) | 9/74 (12.2%) |
| - Follicular lymphoma (FL) | 2/30 (6.7%) | 4/44 (9.0%) | 6/74 (8.1%) |
| - Diffuse large B-cell lymphoma (DLBCL) | 1/30 (3.3%) | 3/44 (6.8%) | 4/74 (5.4%) |
| - Chronic lymphocytic leukemia (CLL) | 0/30 (0%) | 1/44 (2.3%) | 1/74 (1.4%) |
| - Peripheral T-cell lymphoma, not otherwise specified | 0/30 (0%) | 1/44 (1.4%) | 1/74 (1.4%) |
| Conjunctival lymphoma | 7/30 (23.3%) | 11/44 (25.0%) | 18/74 (24.3%) |
| Orbital lymphoma | 23/30 (76.7%) | 33/44 (75.0%) | 56/74 (75.7%) |
Specifications of orbital and conjunctival lymphomas
| Orbital lymphomas | Conjunctival lymphomas | All | |
|---|---|---|---|
| Unilateral lymphoma | 46/56 (82.1%) | 17/18 (94.4%) | 63/74 (85.1%) |
| Bilateral lymphoma | 10/56 (17.9%) | 1/18 (5.6%) | 11/74 (14.9%) |
| Lymphoma type | |||
| - Marginal zone lymphoma (MALT) | 36/56 (64.3%) | 17/18 (94.4%) | 53/74 (71.6%) |
| - Mantle cell lymphoma (MCL) | 9/56 (16.1%) | 0/18 (0%) | 9/74 (12.2%) |
| - Follicular lymphoma (FL) | 5/56 (8.9%) | 1/18 (5.6%) | 6/74 (8.1%) |
| - Diffuse large B-cell lymphoma (DLBCL) | 4/56 (7.1%) | 0/18 (0%) | 4/74 (5.4%) |
| - Chronic lymphocytic leukemia (CLL) | 1/56 (1.8%) | 0/18 (0%) | 1/74 (1.4%) |
| - Peripheral T-cell lymphoma, not otherwise specified | 1/56 (1.8%) | 0/18 (0%) | 1/74 (1.4%) |